

Editor's Note

- Introducing The Clinical Connection.**
Kenneth C. Anderson, Senior Editor.....3761

The Clinical Connection

- Triggering Tumor Immunity through Angiogenesis Targeting.**
□□ *Commentary on Manning et al., p. 3951*
Masahisa Jinushi and Glenn Dranoff.....3762

CCR Drug Updates

- Sorafenib and Sunitinib in Renal Cell Carcinoma.**
Mark N. Stein and Keith T. Flaherty3765

Molecular Pathways

- Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma.** Hashem Younes, Xavier Leleu, Evdoxia Hatjiharissi, Anne-Sophie Moreau, Teru Hideshima, Paul Richardson, Kenneth C. Anderson, and Irene M. Ghobrial3771

Review

- Cancer Vaccines: Moving Beyond Current Paradigms.** Jeffrey Schlom, Philip M. Arlen, and James L. Gulley.....3776

Human Cancer Biology

- Cytochrome P450 17A1 and Catechol O-Methyltransferase Polymorphisms and Age at Lynch Syndrome Colon Cancer Onset in Newfoundland.** Peter T. Campbell, Laura Edwards, John R. McLaughlin, Jane Green, H. Banfield Younghusband, and Michael O. Woods3783

- Transcriptional Functionality of Germ Line p53 Mutants Influences Cancer Phenotype.** Paola Monti, Yari Ciribilli, Jennifer Jordan, Paola Menichini, David M. Umbach, Michael A. Resnick, Lucio Luzzatto, Alberto Inga, and Gilberto Fronza.....3789

- Age-Related DNA Methylation Changes in Normal Human Prostate Tissues.** Bernard Kwabi-Addo, Woonbok Chung, Lanlan Shen, Michael Ittmann, Thomas Wheeler, Jaroslav Jelinek, and Jean-Pierre J. Issa.....3796

- Expression of Ral GTPases, Their Effectors, and Activators in Human Bladder Cancer.** Steven Christopher Smith, Gary Oxford, Alexander S. Baras, Charles Owens, Dmytro Havaleshko, David L. Brautigan, Martin K. Safo, and Dan Theodorescu.....3803

- Identification and Clinical Significance of Mobilized Endothelial Progenitor Cells in Tumor Vasculogenesis of Hepatocellular Carcinoma.** Decai Yu, Xitai Sun, Yudong Qiu, Jianxing Zhou, Yafu Wu, Lingyuan Zhuang, Jun Chen, and Yitao Ding.....3814

Imaging, Diagnosis, Prognosis

- Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma.** Bruce Elliott, Richard A. Scolyer, Stefan Suci, Serge Lebecque, Donata Rimoldi, Oliver Gugerli, Elena Musat, Raghwa N. Sharma, Danielle Lienard, Ulrich Keilholz, Alessandro Testori, Alexander Eggermont, Rona MacKie, Caroline Robert, Martin Cook, John F. Thompson, Eric Angevin, and Alain Spatz on behalf of the European Organization for Research and Treatment of Cancer Melanoma Group.....3825

Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer. Alberto Malesci, Luigi Laghi, Paolo Bianchi, Gabriele Delconte, Ann Randolph, Valter Torri, Carlo Carnaghi, Roberto Doci, Riccardo Rosati, Marco Montorsi, Massimo Roncalli, Leandro Gennari, and Armando Santoro.....	3831
Detection of MAGE-A Transcripts in Bone Marrow Is an Independent Prognostic Factor in Operable Non–Small-Cell Lung Cancer. Wulf Sienel, Ingo Mecklenburg, Sebastian Dango, Peter Ehrhardt, Andreas Kirschbaum, Bernward Passlick, and Klaus Pantel	3840
Up-regulation of Tumor Susceptibility Gene 101 Conveys Poor Prognosis through Suppression of p21 Expression in Ovarian Cancer. Travis W. Young, Daniel G. Rosen, Fang C. Mei, Nan Li, Jinsong Liu, Xiao-Fan Wang, and Xiaodong Cheng	3848
Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Adriana Handra-Luca, Juana Hernandez, Giannis Mountzios, Estelle Taranchon, Jean Lacau-St-Guily, Jean-Charles Soria, and Pierre Fouret	3855
Determining Risk of Biochemical Recurrence in Prostate Cancer by Immunohistochemical Detection of PTEN Expression and Akt Activation. Roble Bedolla, Thomas J. Prihoda, Jeffrey I. Kreisberg, Shazli N. Malik, Naveen K. Krishnegowda, Dean A. Troyer, and Paramita M. Ghosh	3860
Prognostic Significance of the Immunohistochemical Staining of Cleaved Caspase-3, an Activated Form of Caspase-3, in Gliomas. Tatsuya Kobayashi, Junya Masumoto, Tsuyoshi Tada, Tetsuo Nomiyama, Kazuhiro Hongo, and Jun Nakayama.....	3868
Elevated Peroxiredoxin 1, but not NF-E2–Related Factor 2, Is an Independent Prognostic Factor for Disease Recurrence and Reduced Survival in Stage I Non–Small Cell Lung Cancer. Joo-Heon Kim, Paul N. Bogner, Nithya Ramnath, Yoorim Park, Jihnhee Yu, and Young-Mee Park	3875

Cancer Therapy: Clinical

Granulocyte Macrophage Colony-Stimulating Factor–Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer. Eric J. Small, Natalie Sacks, John Nemunaitis, Walter J. Urba, Eugene Dula, Arthur S. Centeno, William G. Nelson, Dale Ando, Catherine Howard, Flavia Borellini, Minh Nguyen, Kristen Hege, and Jonathan W. Simons.....	3883
Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non–Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program. Martin Filipits, Vincent Haddad, Katharina Schmid, Anh Huynh, Ariane Dunant, Fabrice André, Elisabeth Brambilla, Rolf Stahel, Jean-Pierre Pignon, Jean-Charles Soria, Helmut H. Popper, Thierry Le Chevalier, and Robert Pirker	3892
Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study. Alexander Burges, Pauline Wimberger, Carolin Kümper, Vera Gorbounova, Harald Sommer, Barbara Schmalfeldt, Jacobus Pfisterer, Michail Lichinitser, Anatoliy Makhson, Vladimir Moiseyenko, Angelika Lahr, Elisabeth Schulze, Michael Jäger, Michael A. Ströhlein, Markus Maria Heiss, Thomas Gottwald, Horst Lindhofer, and Rainer Kimmig.....	3899
A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183. Linda E. Bröker, Stephan A. Veltkamp, Elisabeth I. Heath, Bart C. Kuenen, Helen Gall, Ludovic Astier, Susan Parker, Louis Kayitalire, Patricia M. Lorusso, Jan H.M. Schellens, and Giuseppe Giaccone.....	3906
Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies. Bret Wacker, Tina Nagrani, Jacqueline Weinberg, Karsten Witt, Gary Clark, and Pablo J. Cagnoni	3913

Cancer Therapy: Preclinical


- Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104.** Adam V. Patterson, Dianne M. Ferry, Shelley J. Edmunds, Yongchuan Gu, Rachelle S. Singleton, Kashyap Patel, Susan M. Pullen, Kevin O. Hicks, Sophie P. Syddall, Graham J. Atwell, Shangjin Yang, William A. Denny, and William R. Wilson.....3922
- Histone Deacetylase Inhibitors Affect Dendritic Cell Differentiation and Immunogenicity.** Alessio Nencioni, Julia Beck, Daniela Werth, Frank Grünebach, Franco Patrone, Alberto Ballestrero, and Peter Brossart3933
- Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy.** Paxton V. Dickson, John B. Hamner, Thomas L. Sims, Charles H. Fraga, Catherine Y.C. Ng, Surender Rajasekeran, Nikolaus L. Hagedorn, M. Beth McCarville, Clinton F. Stewart, and Andrew M. Davidoff.....3942
- A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism.** Elizabeth A. Manning, John G.M. Ullman, James M. Leatherman, Justin M. Asquith, Timothy R. Hansen, Todd D. Armstrong, Daniel J. Hicklin, Elizabeth M. Jaffee, and Leisha A. Emens3951
- An Imageable Metastatic Treatment Model of Nasopharyngeal Carcinoma.** Tengfei Liu, Yanqin Ding, Weibing Xie, Zuguo Li, Xiaoyan Bai, Xin Li, Weiyi Fang, Caiping Ren, Shuang Wang, Robert M. Hoffman, and Kaitai Yao3960
- Adeno-Associated Virus–Mediated Antiangiogenic Gene Therapy with Thrombospondin-1 Type 1 Repeats and Endostatin.** Xuefeng Zhang, Jianfeng Xu, Jack Lawler, Ernest Terwilliger, and Sareh Parangi3968
- Combined Therapeutic Effects of Vinblastine and Rapamycin on Human Neuroblastoma Growth, Apoptosis, and Angiogenesis.** Danilo Marimpietri, Chiara Brignole, Beatrice Nico, Fabio Pastorino, Annalisa Pezzolo, Federica Piccardi, Michele Cilli, Daniela Di Paolo, Gabriella Pagnan, Luca Longo, Patrizia Perri, Domenico Ribatti, and Mirco Ponzoni3977
- A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays.** Elisabetta Marangoni, Anne Vincent-Salomon, Nathalie Auger, Armelle Degeorges, Franck Assayag, Patricia de Cremoux, Ludmilla de Plater, Charlotte Guyader, Gonzague De Pinieux, Jean-Gabriel Judde, Magali Rebutti, Carine Tran-Perennou, Xavier Sastre-Garau, Brigitte Sigal-Zafrani, Olivier Delattre, Véronique Diéras, and Marie-France Poupon3989
- A Novel Alphavirus Vaccine Encoding Prostate-Specific Membrane Antigen Elicits Potent Cellular and Humoral Immune Responses.** Robert J. Durso, Sofija Andjelic, Jason P. Gardner, Dennis J. Margitich, Gerald P. Donovan, Robert R. Arrigale, Xinning Wang, Maureen F. Maughan, Todd L. Talarico, Robert A. Olmsted, Warren D.W. Heston, Paul J. Maddon, and William C. Olson3999
- Rebuilding Human Leukocyte Antigen Class II–Restricted Minor Histocompatibility Antigen Specificity in Recall Antigen-Specific T Cells by Adoptive T Cell Receptor Transfer: Implications for Adoptive Immunotherapy.** Robbert Spaapen, Kelly van den Oudenalder, Roman Ivanov, Andries Bloem, Henk Lokhorst, and Tuna Mutis.....4009
- Immune Signatures of Murine and Human Cancers Reveal Unique Mechanisms of Tumor Escape and New Targets for Cancer Immunotherapy.** Rebecca E. Sadun, Suzanne M. Sachsman, Xiaoying Chen, Kamilee W. Christenson, William Z. Morris, Peisheng Hu, and Alan L. Epstein.....4016

Letters to the Editor

- Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.** Birgit C. Schultes, L. Mary Smith, and Christopher F. Nicodemus4026
- Reply to the Letter to the Editor from Schultes et al.** Paul Sabbatini and Kunle Odunsi4026
- Obesity and Treatment of Prostate Cancer: What Is the Right Dose of Lupron Depot?** Neeraj Agarwal, Deborah Fletcher, and John Ward.....4027

About the Cover

Treatment of established mammary tumors with the VEGF-R2-specific antibody DC101 alone inhibits tumor growth by decreasing angiogenesis and increasing apoptosis. DC101 treatment by itself induces tumor-specific T-cell responses, and integrating DC101 with vaccination enhances tumor-free survival and tumor-specific T-cell responses in the absence of immune tolerance. These findings establish the induction of tumor-specific T-cell responses as one consequence of VEGF-R2-targeting with DC101. For further details, please see Manning *et al.* on page 3951 in this issue.



Clinical Cancer Research

13 (13)

Clin Cancer Res 2007;13:3761-4031.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/13/13>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/13/13>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.